Clinical trials: Hot Flashes
Menopause, Hot Flashes
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
This is a proof-of-concept phase 2 clinical trial to investigate the effect of the phytoestrogenic supplement PhytoSERM on vasomotor symptoms and other symptoms associated with the menopausal transition, and on blood-based…
- Trial name
- HF-Relief (NCT06186531)
- Testing
- PhytoSERM
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- NeuTherapeutics
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but…
- Trial name
- NCT06440967
- Testing
- Fezolinetant, Tamoxifen, Aromatase inhibitor
- Where
- 110 sites in Canada, Czechia and 9 more
- Volunteers
- 982 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hot Flashes
FP-101 for the Treatment of Hot Flashes in Postmenopausal Women
The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT03285672
- Testing
- FP-101
- Where
- 12 sites in United States
- Volunteers
- 109 people
- Sponsor
- Fervent Pharmaceuticals
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). The symptoms of VMS are hot flashes. These symptoms can be caused by changes in sex hormone levels.
- Trial name
- NCT05071729
- Testing
- Elinzanetant (BAY3427080)
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
Hot Flashes
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
- Trial name
- NCT00314964
- Testing
- PD-0299685
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 527 people
- Sponsor
- Pfizer
Adenocarcinoma, Prostate
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
The purpose of this study is to compare the efficacy of three drugs (cyproterone acetate, medroxyprogesterone acetate and venlafaxine) in the treatment of hot flushes caused by leuprorelin LP 11.25 milligram (mg) in participants…
- Trial name
- NCT01011751
- Testing
- Cyproterone acetate, Medroxyprogesterone acetate, Venlafaxine
- Where
- France
- Volunteers
- 311 people
- Sponsor
- Takeda
Hot Flashes
A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
This study is for menopausal women who have hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life.
- Trial name
- Starlight (NCT05034042)
- Testing
- Fezolinetant
- Where
- 40 sites in Japan
- Volunteers
- 147 people
- Sponsor
- Astellas Pharma Inc
Menopause, Menopausal Symptoms
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
This study evaluates the effects of Primal Harvest's Primal Meno+ supplement on symptoms of menopause and overall well-being in females aged 40-60 who are currently menopausal and experiencing at least two menopausal symptoms.
- Conditions
- Menopause, Menopausal Symptoms, Hot Flashes, Night Sweats
- Trial name
- NCT07903480
- Testing
- Primal Meno+ Supplement
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Primal Harvest, LLC
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.
Vasomotor Symptoms
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
- Trial name
- NCT00683800
- Testing
- desvenlafaxine succinate (DVS) SR
- Where
- 121 sites in United States, Canada
- Volunteers
- 2,186 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hot Flashes
A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms).
- Trial name
- GRACE (NCT07455812)
- Testing
- Fezolinetant
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Europe Ltd.
Menopause, Menopausal Symptoms
Effect of HIFAS MENOPAUSE on Quality of Life in Postmenopausal Women
This single-center, single-group, open-label study evaluated changes in menopause-related quality of life and menopausal symptoms in postmenopausal women aged 40 to 60 years after 24 weeks of treatment with HIFAS MENOPAUSE.
- Trial name
- NCT07752641
- Testing
- HIFAS MENOPAUSE
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hifas da Terra S.L.
Hot Flushes, Menopause, Postmenopause
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet…
- Trial name
- NCT00160342
- Testing
- Esterified Estrogens (EE) and Methyltestosterone (MT)
- Where
- 125 sites in United States, Canada and 1 more
- Volunteers
- 1,251 people
- Sponsor
- Solvay Pharmaceuticals
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra
Hot Flashes
Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
- Trial name
- NCT04278872
- Testing
- SJX-653
- Where
- 22 sites in Belgium, Germany and 2 more
- Volunteers
- 13 people
- Sponsor
- Sojournix, Inc.
Hot Flashes, Prostate Cancer
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
- Trial name
- NCT00005623
- Testing
- cyproterone acetate, quality-of-life assessment
- Where
- United States
- Sponsor
- Barr Laboratories
Hot Flashes
Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women
- Trial name
- NCT00777023
- Testing
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg
- Where
- 45 sites in United States
- Volunteers
- 565 people
- Sponsor
- Depomed
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer…
- Trial name
- OASIS-4 (NCT05587296)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 102 sites in Austria, Belgium and 14 more
- Volunteers
- 474 people
- Sponsor
- Bayer
Menopause, Menopausal Vasomotor Symptoms
Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations
This trial is conducted in Europe. Postmenopausal women with moderate to severe hot flashes have been recruited into the trial. The earliest effect of ultra low dose HRT (hormone replacement therapy) on frequency and severity of…
- Trial name
- CHOICE (NCT00184795)
- Testing
- 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA), 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
- Where
- 91 sites in Austria, Belgium and 8 more
- Volunteers
- 576 people
- Sponsor
- Novo Nordisk A/S
Moderate to Severe Vasomotor Symptoms in Postmenopausal, Women
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women.
- Trial name
- NCT01015677
- Testing
- MK-6913, 17-β estradiol, MK-6913 25 mg
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC